Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Terminated 3Unknown 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Gastrointestinal Stromal Tumors 8Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia 2Hematologic Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor Cancer 1Rare Tumor 1Rare Malignant Neoplasm 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Melanoma 1Lymphangioleiomyomatosis 1Leukemia, Myeloid, Chronic-Phase 1Digestive System Neoplasms 1Congenital Bone Marrow Failure Syndromes 1Burkitt Lymphoma 1Breast Neoplasms 1Blast Crisis 1

Interventions

pembrolizumab 54Nivolumab 50Ipilimumab 28Cyclophosphamide 16binimetinib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10fludarabine 9Radiosurgery 9relatlimab 8encorafenib 8Opdualag 8Biopsy 8aldesleukin 7Interleukin-2 7atezolizumab 6Immunotherapy 6Blood Specimen Collection 6cemiplimab 5CTLA-4 Antigen 5Bevacizumab 5trametinib 4fludarabine phosphate 4dabrafenib 4Temozolomide 4Paclitaxel 4Immune Checkpoint Inhibitors 4spartalizumab 3Surgical Procedures, Operative 3Metformin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Melanoma × Imatinib Mesylate × Clear all
NCT04598009 2026-06-04

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

University of California, San Francisco

Phase 2 Recruiting
25 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡